US Interchangeability ‘Irrelevant’ And ‘Makes No Sense’ Says Sandoz
CEO And North America Head Discuss Evolving FDA Approach To Biosimilars
Executive Summary
At the recent Morgan Stanley Healthcare Conference in New York, Sandoz leaders set out their views on the significance of – and the FDA’s initial implementation of – the US biosimilar interchangeability designation.